Under-eye filler or lower blepharoplasty?

<!-- warmstart-de-revision: warmstart-de:page:surgeryviz:under-eye-filler-vs-lower-bleph:b633e5dc43336fa426b9146ad2e14e7beab272b56c41aeb12faf597333d9d4e9 -->

TL;DR

• Pinch >6–8 mm or positive snap test → lower blepharoplasty, not filler.
• Isolated tear-trough groove + good skin → hyaluronic acid filler is appropriate.
• Surgery: $5,000–$10,000 once, 10–15 years structurally, 1–5% ectropion risk.
• Filler: $600–$1,500/syringe, 6–18 months, 0.001–0.01% blindness risk.
• Cumulative filler cost crosses surgery cost around year 5–7.

For isolated tear-trough hollows in patients with good skin elasticity and no fat prolapse, hyaluronic acid filler offers a reversible, lower-cost entry point. For patients who can pinch more than 6–8 mm of loose lower-lid skin, have a positive snap test, or visible fat bags, lower blepharoplasty is the appropriate structural solution because filler camouflages volume loss but cannot correct skin laxity or herniated fat—and may create puffiness or the Tyndall effect. Surgery costs $5,000–$10,000 once, lasts 10–15 years structurally, and carries a 1–5% ectropion risk but no filler-related blindness risk. Filler costs $600–$1,500 per syringe, lasts 6–18 months, and carries a 0.001–0.01% risk of vision loss from vascular occlusion. The cumulative cost crossover occurs around years 5–7, after which surgery is usually cheaper. Our confidence: it depends — the right answer changes with your situation.

The Anatomy That Determines Your Path

Aging lower eyelids involve fat prolapse, volume loss, and skin redundancy; filler only camouflages volume loss and can worsen fat prolapse or skin laxity.

The lower eyelid is a suspension system: the orbicularis oculi muscle, three fat compartments (medial, central, lateral), and the orbital septum. Aging occurs in three dimensions simultaneously:

• Fat prolapse: The orbital septum weakens, allowing periorbital fat to herniate forward and create bags.
• Volume loss: The maxilla resorbs and descends, creating a valley (tear trough) between the lower lid and cheek.
• Skin redundancy: Dermatochalasis—excess, inelastic skin—may drape over the lid margin or create crepey texture.

Filler camouflages volume loss but cannot fix fat prolapse or skin laxity. Injecting filler above herniated fat or into loose skin often creates a puffy appearance surgeons call filler-induced festoons.

The Three Tests You Can Do Now

Use the pinch test, snap test, and bulge test to triage whether your anatomy favors filler, surgery, or an oculoplastic consultation.

Pinch test: Gently pinch the skin of your lower eyelid. If you can grasp more than 6–8 mm of skin or it feels paper-thin and slow to retract, you have dermatochalasia. This finding contraindicates standalone filler therapy.

Snap test: Pull the lower eyelid down and away from the globe, then release. It should snap back within one second. Slow return or lid lag indicates lid laxity, which increases ectropion risk after surgery and may require a canthopexy.

Bulge test: Look upward and gently press on your closed eyelid. Distinct, spongy protrusions pushing back indicate fat herniation, which requires surgical excision or repositioning.

The Comparison: Numbers That Matter

Filler is reversible and lower-cost upfront but temporary; blepharoplasty is permanent structural correction with higher initial cost and surgical downtime.

Hyaluronic acid filler is indicated for isolated tear-trough deformity without skin laxity or fat prolapse, typically in younger patients. It lasts 6–18 months, costs roughly $600–$1,500 per syringe, is reversible with hyaluronidase, and has a 0.001–0.01% risk of blindness from vascular occlusion.

Lower blepharoplasty is indicated for excess skin, fat herniation, or muscle laxity. It costs $5,000–$10,000 total, lasts 10–15 years structurally, carries a 1–5% ectropion risk with transcutaneous approaches, and has no filler-related blindness risk. Patient satisfaction is 87–95% at 12 months.

Recovery is 24–48 hours for filler versus 10–14 days for surgery. By year 5–7, cumulative filler expenses typically exceed a single surgical correction.

When Filler Makes It Worse: The Heaviness Paradox

Filler placed above herniated fat or in loose skin can cause persistent puffiness, the Tyndall effect, and lymphatic malar edema.

Filler is hydrophilic, attracting water. In thin lower-eyelid skin (about 0.5 mm versus 2 mm in the cheek), or above herniated fat pads, it creates persistent edema that reads as puffiness.

The Tyndall effect—a bluish discoloration from superficial placement—occurs in 9–15% of tear-trough treatments and requires dissolution with hyaluronidase.

Repeated injections can also disrupt delicate lymphatic drainage, causing malar edema (upper-cheek swelling) that may persist for months after the filler has dissolved.

Risk Profiles: Blindness vs. Ectropion

Filler's catastrophic risk is irreversible blindness from vascular occlusion; surgery's main risk is ectropion or scleral show, usually correctable with revision.

Filler risk: The angular artery and its branches supply the retina via the ophthalmic artery. Intravascular injection or external vessel compression can send filler retrograde to the central retinal artery, causing immediate, irreversible blindness. The incidence is estimated at 0.001–0.01%. Risk is reduced but not eliminated by cannula technique, deep pre-periosteal placement, and aspiration. Treatment is an emergency high-dose retrobulbar hyaluronidase protocol.

Surgical risk: Transcutaneous lower blepharoplasty can disrupt lower-lid suspensory ligaments. If excessive skin is removed or lid tone is poor, the lid margin pulls downward (ectropion) or sclera shows below the iris (scleral show). This occurs in 1–5% of transcutaneous cases and <1% of transconjunctival cases. It is usually correctable with revision surgery or canthopexy.

Key numbers

• >6–8 mm — Lower-eyelid skin-laxity pinch-test threshold [1]
• 6–18 months — Hyaluronic acid filler longevity [2]
• 0.001–0.01% — Filler blindness risk from vascular occlusion [3]
• $5,000–$10,000+ — Lower blepharoplasty cost range [4]
• 1–5% — Ectropion risk after transcutaneous lower blepharoplasty [5]
• 10–15 years — Structural longevity of lower blepharoplasty [6]
• ~5–7 years — Filler-to-surgery cumulative cost crossover [7]
• 9–15% — Tyndall effect incidence after tear-trough filler [8]
• 87–95% — Patient satisfaction after lower blepharoplasty at 12 months [9]

Cost comparison

Our take

Start with the three self-tests to understand your anatomy. If your anatomy clearly favors one option, choose that path with an appropriately qualified provider. If you are in the 35–45 age range with mixed findings, an oculoplastic consultation for possible fat-preserving surgery is usually wiser than repeated filler. When uncertain, waiting 6–12 months costs nothing and avoids difficult revisions.

FAQ

Can under-eye filler fix eye bags?

No. Filler camouflages volume loss but cannot fix fat prolapse or skin laxity. Injecting filler above herniated fat can create a puffy, overfilled appearance sometimes called filler-induced festoons. [1]

What is the risk of blindness from under-eye filler?

The estimated incidence is 0.001–0.01% (1–10 per 100,000 injections). It is caused by vascular occlusion of the angular artery, which can travel retrograde to the central retinal artery. It is an emergency requiring immediate high-dose hyaluronidase. [1]

How long does lower blepharoplasty last?

Structural results last 10–15 years. Fat repositioning is permanent, though natural aging continues and may eventually create new changes. [1]

When does filler become more expensive than lower blepharoplasty?

The cumulative cost crossover point is approximately year 5–7. By year 10, annual filler maintenance can total around $13,500, versus a one-time surgery cost of roughly $7,500. [1]

Who is not a candidate for under-eye filler?

Patients with more than 6–8 mm of pinchable skin, visible fat bags, a history of malar edema, very thin sun-damaged skin, or those seeking permanent fillers near the eye should avoid standalone tear-trough filler. [1]

Is lower blepharoplasty covered by insurance?

Lower blepharoplasty is usually cosmetic. It may be covered only if lower-lid skin excess causes mechanical ectropion with documented visual field loss, standardized photography, and failed conservative measures. [1]

Sources

1. AAFPRS — Lower Eyelid Rejuvenation — unverified
2. ASOPRS — Patient Safety: Filler Injections Around the Eye — unverified
3. ASPS — Clinical Practice Guideline: Blepharoplasty — unverified
4. Scheuer JF et al. — Filler longevity and cost analysis in facial rejuvenation — unverified
5. Goldberg RA et al. — What causes eyelid bags? — unverified
6. ASOPRS — Lower Eyelid Blepharoplasty Patient Education — unverified
7. Kakizaki H et al. — Anatomy of the lower eyelid and its age-related changes — unverified
8. Pessa JE et al. — Fat herniation and the tear trough deformity — unverified
9. Funt DK, Pavicic T. — Dermal fillers in aesthetics: an overview of adverse events — unverified
10. Nassif PS et al. — Long-term outcomes in lower blepharoplasty — unverified
11. ASPS — 2023 Plastic Surgery Statistics Report — unverified
12. Carle MV et al. — Visual loss after facial filler injection — unverified
13. Bartley GB et al. — Complications of blepharoplasty — unverified
14. FDA — Dermal Fillers (Soft Tissue Fillers) — unverified
15. Codner MA et al. — Patient satisfaction and outcomes in lower eyelid surgery — unverified
16. Rohrich RJ et al. — Fluid compartments of the lower eyelid — unverified
17. Scheuer JF et al. — Malar edema after tear trough filler — unverified
18. Lazzeri D et al. — Blindness following cosmetic injections of the face — unverified
19. Hoenig JA et al. — Lower blepharoplasty: transconjunctival vs transcutaneous approach — unverified
20. Hamako C et al. — Fat transposition versus fat removal in lower blepharoplasty — unverified
21. CMS — Local Coverage Determination: Blepharoplasty (L33446) — unverified

*Educational only; not a diagnosis, medical advice, or a substitute for an in-person consultation.*